Sanofi ADR (SNY) - Stock Price & Dividends

Exchange: USA Stocks • Country: France • Currency: USD • Type: Common Stock • ISIN: US80105N1054

Vaccines, Diabetes, Oncology, Cardiovascular, Neurology, Skincare, Pediatrics

Sanofi, a leading healthcare company, is dedicated to improving lives through innovative therapeutic solutions. With a strong presence in the United States, Europe, and globally, the company focuses on research, development, manufacturing, and marketing of a wide range of healthcare products.

The company operates through three main segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. In the Pharmaceuticals segment, Sanofi offers specialty care products, including DUPIXENT, neurology and immunology treatments, rare disease medications, oncology therapies, and treatments for rare blood disorders. The company also provides medications for diabetes and cardiovascular diseases, as well as established prescription products.

In the Vaccines segment, Sanofi offers a comprehensive range of vaccines, including pediatric vaccines for poliomyelitis, pertussis, and hib, as well as influenza, booster, meningitis, and travel and endemic vaccines. The company's vaccine portfolio includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines, protecting people from various diseases worldwide.

The Consumer Healthcare segment offers a diverse range of products, including cough, cold, and flu medications, allergy treatments, and pain care products. Additionally, the company provides physical, mental, and digestive wellness products, as well as skincare products for various needs, including eczema, itching, hydration, aging, cracking, and overnight skincare.

Sanofi is committed to innovation and collaboration, with several partnerships and agreements in place. The company has collaborations with Exscientia to develop novel small-molecule oncology and immunology treatments, ABL Bio to develop ABL301 for alpha-synucleinopathies, and Blackstone Life Sciences to develop pivotal studies and clinical development programs. Sanofi also has agreements with Seagen Inc. to develop antibody-drug conjugates for cancer, IGM Biosciences to develop IgM antibody, Skyhawk Therapeutics to discover and develop novel small molecules, and Adagene Inc. for antibody-based therapies.

Furthermore, Sanofi has collaborations with Scribe Therapeutics to develop genome editing technologies and a co-promotion service agreement with Provention Bio for the commercialization of teplizumab. Founded in 1973, Sanofi is headquartered in Paris, France, and was formerly known as Sanofi-Aventis before changing its name in May 2011. For more information, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Sanofi ADR (SNY) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Sanofi ADR (SNY) - Stock Price & Dividends

SNY Stock Overview

Market Cap in USD 118,113m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2002-07-01

SNY Stock Ratings

Growth 5y 22.3
Fundamental 44.0
Dividend 6.94
Rel. Performance vs Sector -2.36
Analysts 4.50/5
Fair Price Momentum 43.46 USD
Fair Price DCF 76.74 USD

SNY Dividends

Yield 12m 4.31%
Yield on Cost 5y 5.40%
Dividends CAGR 5y 1.79%
Payout Consistency 97.0%

SNY Growth Ratios

Growth 12m -11.43%
Growth Correlation 12m -35%
Growth Correlation 3m 3%
CAGR 5y 4.58%
CAGR/Mean DD 5y 0.55
Sharpe Ratio 12m -0.61
Alpha vs SP500 12m -29.79
Beta vs SP500 5y weekly 0.59
ValueRay RSI 24.52
Volatility GJR Garch 1y 23.00%
Price / SMA 50 -1.97%
Price / SMA 200 -3.85%
Current Volume 4986.7k
Average Volume 20d 2416.8k

External Links for SNY Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of SNY stocks?
As of June 22, 2024, the stock is trading at USD 47.21 with a total of 4,986,733 shares traded.
Over the past week, the price has changed by +2.08%, over one month by -3.55%, over three months by -1.09% and over the past year by -11.99%.
What are the forecast for SNY stock price target?
According to ValueRays Forecast Model, SNY Sanofi ADR will be worth about 47.7 in June 2025. The stock is currently trading at 47.21. This means that the stock has a potential upside of +1%.
Issuer Forecast Upside
Wallstreet Target Price 59.1 25.2
Analysts Target Price 65.1 38.0
ValueRay Target Price 47.7 1.00

Sanofi ADR: A Comprehensive Overview

History of Sanofi ADR

Sanofi ADR, part of the global healthcare leader Sanofi, has a rich history dating back to its establishment. It emerged from a series of mergers and acquisitions, most notably the union of Sanofi-Synthélabo and Aventis in 2004, forming one of the world's foremost pharmaceutical giants. Based in France, Sanofi has expanded its operations globally, establishing a strong presence in both developed and emerging markets.

Core Business

At its core, Sanofi is dedicated to improving health outcomes by developing, manufacturing, and marketing pharmaceutical drugs and vaccines. Its product portfolio includes a wide range of medications for conditions such as diabetes, rare diseases, multiple sclerosis, and oncology. Sanofi also possesses a significant footprint in the consumer healthcare sector, offering over-the-counter (OTC) medications that address everyday health concerns.

Side Businesses and Diversification

Beyond its primary pharmaceutical operations, Sanofi has diversified its business. This includes its investments in biotechnology and its venture into digital health solutions. Additionally, Sanofi's Genzyme division focuses on rare diseases and rare blood disorders, setting the company apart in highly specialized areas of medicine. The company has also been proactive in forging partnerships and collaborations that further its research capabilities and expand its market reach.

Current Market Status

Currently, Sanofi ADR (NASDAQ:SNY) remains a strong player in the pharmaceutical industry. It has demonstrated resilience and adaptability in a rapidly evolving market, often marked by increasing regulatory pressures and intense competition. With its strategic focus on innovation, especially in biotech and digital health, Sanofi aims to position itself at the forefront of healthcare advancements. Financially, it continues to exhibit robust performance, with steady revenue growth and a promising pipeline of future products.